Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023

Rhea-AI Summary

Cara Therapeutics has announced an upcoming Capital Markets Day scheduled for February 16, 2023, in New York City, focusing on its new treatment for pruritus. The event will cover the launch of KORSUVA® (difelikefalin) injection, highlighting its role in addressing pruritus related to chronic kidney disease and other conditions. Key presentations will include insights into the unmet medical needs and the ongoing Phase 2/3 trials of oral difelikefalin for notalgia paresthetica. Attendees can register online, and a live webcast will be available on the company’s website.

STAMFORD, Conn., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host an in-person and virtual Capital Markets Day in New York City on Thursday, February 16, 2023, from 10:00 a.m. to 1:00 p.m. EST.

The event will highlight the launch of KORSUVA^® (difelikefalin) injection and feature presentations during which healthcare providers will discuss the unmet medical need in pruritus associated with non-dialysis dependent chronic kidney disease, atopic dermatitis and notalgia paresthetica. The Company’s registrational Phase 2/3 program of oral difelikefalin in notalgia paresthetica patients with moderate-to-severe pruritus will also be discussed.

Presenters will include:

• Christopher Posner, President and Chief Executive Officer, Cara Therapeutics
• Joana Goncalves, M.D., Chief Medical Officer, Cara Therapeutics
• Eric Vandal, Senior Vice President, Commercial, Cara Therapeutics
• Joel Topf, M.D., FACP, Assistant Clinical Professor of Medicine at Oakland University William Beaumont School of Medicine, and Medical Director of St. Clair Nephrology Research
• Jennifer Scherer, M.D., Assistant Professor of Palliative Care and Nephrology at the NYU Grossman School of Medicine, and Director of the Kidney CARES Program at NYU Langone Health
• Raj Chovatiya, M.D., Ph.D., Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine, and Director of the Center for Eczema and Itch at Northwestern University
• Shawn Kwatra, M.D., FAAD, Assistant Professor of Dermatology at the Johns Hopkins University School of Medicine, and Director of the Johns Hopkins Itch Center
  

To register for the event, please click here.

A live webcast of the event will be accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. A replay of the webcast will be archived on the Company’s website following the event.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA^® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

What is the date and location of Cara Therapeutics' Capital Markets Day?

Cara Therapeutics' Capital Markets Day is scheduled for February 16, 2023, in New York City.

What will be discussed at the Capital Markets Day hosted by Cara Therapeutics?

The event will discuss the launch of KORSUVA® injection and the need for treatments for pruritus associated with chronic kidney disease and other conditions.

Who are the presenters at the Cara Therapeutics Capital Markets Day?

Presenters include Christopher Posner, Joana Goncalves, Eric Vandal, and several prominent doctors in nephrology and dermatology.

How can I register for the Cara Therapeutics Capital Markets Day event?

You can register for the event by clicking the registration link provided in the press release.

Will there be a webcast of the Cara Therapeutics Capital Markets Day?

Yes, a live webcast of the event will be accessible on the Cara Therapeutics website.

What is KORSUVA® and its significance in Cara Therapeutics' offerings?

KORSUVA® (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease.

What clinical trials is Cara Therapeutics currently conducting?

Cara Therapeutics is conducting Phase 2/3 clinical trials for oral difelikefalin aimed at treating notalgia paresthetica.